A multicenter, randomized, double-blind, placebo-controlled, parallel-design, exploratory pharmacogenomic, safety and activity study of orally administered ERB-041 in subjects with inflammation associated with active Crohn's disease
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2009
At a glance
- Drugs Prinaberel (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 22 Sep 2009 New trial record.